Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

Overview of attention for article published in Cost Effectiveness and Resource Allocation, November 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

blogs: 1 blog
policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 68 Mendeley

Summary Blogs Policy documents X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 2,173 followers.

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective https://t.co/cMUIADkeAf https://t.co/72wNqzCmox

17 Nov 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.